GoHealthcare Practice Solutions

Thoracic Intra-Articular Facet Joint Injection

Medical Necessity, Prior Authorization, Documentation, Coding, Reimbursement, and Denial Prevention

The decisive operational question is not merely whether the thoracic facet joints could be painful. It is whether an intra-articular injection is the correct, covered, and documented intervention for the member, payer, level, laterality, and intended diagnostic or therapeutic pathway.

Request Help View Case Studies

GoHealthcare Results

Company-reported operational performance across specialty prior authorization and healthcare practice support engagements.

25+ YearsHealthcare operations experience

500+ Physicians and GroupsServed across specialty practices

3.5M+ Prior AuthorizationsRequests processed

98% Approval RateCompany-reported authorization approval rate

Results vary by client, payer, specialty, case mix, and contracted scope.

Request Help Explore Case Studies

Case Study Library: https://www.gohealthcarellc.com/case-studies.html

How to Use This Resource

This publication is designed for physicians, APPs, practice administrators, prior authorization specialists, utilization management nurses, coders, revenue cycle professionals, ambulatory surgery centers, hospitals, and healthcare executives. It is an operational and reimbursement resource, not a substitute for the member benefit, live payer policy, Medicare contractor instruction, current CPT and ICD-10-CM code sets, or clinician judgment. Verify the controlling policy and code set before each submission, procedure, or claim.

Critical distinction

Thoracic intra-articular facet joint injection is not interchangeable with a thoracic medial branch block, thoracic medial branch radiofrequency ablation, thoracic epidural steroid injection, costotransverse or costovertebral joint injection, intercostal nerve block, or trigger point injection. CPT 64490-64492 can describe injection into a cervical or thoracic facet joint or the nerves innervating that joint, but route, intent, level, laterality, and downstream treatment pathway must be explicit in the order, authorization, procedure report, and claim.

Procedure Navigation

Select a section to review clinical, policy, coding, documentation, reimbursement, or operational requirements.

Sections 1-9

1. Executive Overview
2. Evidence at a Glance
3. Procedure Definition and Relevant Thoracic Anatomy
4. Distinguishing Intra-Articular Injection from Other Facet Procedures
5. Clinical Indications and Patient Selection
6. Contraindications and Safety Considerations
7. Medical Necessity Requirements
8. Conservative Treatment and Care-Pathway Sequencing
9. CMS National Guidance and NCD Review

Sections 10-18

1. Medicare LCD Requirements
2. Medicare Billing and Coding Articles and MAC Variation
3. Medicare Hospital Outpatient Prior Authorization
4. Commercial Payer Policies
5. BCBS Policy Variation
6. Carelon, eviCore, Cohere, and Evolent
7. Clinical Evidence and Specialty-Society Guidance
8. Policy and Guideline Comparison Matrix
9. Prior Authorization Workflow

Sections 19-27

1. Clinical Documentation Requirements
2. Documentation Pearls
3. CPT and HCPCS Coding
4. ICD-10-CM Crosswalk
5. Modifiers, Units, NCCI, MUE, and Place of Service
6. Reimbursement Considerations
7. Denial Prevention
8. Common Denial Reasons and Corrective Actions
9. Appeals and Peer-to-Peer Preparation

Sections 28-36

1. Workflow Optimization and Quality Controls
2. Operational KPIs
3. Payer Perspective
4. Clinical Pearls
5. GoHealthcare Perspective
6. GoHealthcare Insights
7. Frequently Asked Questions
8. Related Procedures
9. References and Related Readings

1

Procedure Library

Executive Overview

A thoracic intra-articular facet joint injection is an image-guided injection of local anesthetic, corticosteroid, or both directly into a thoracic zygapophyseal joint. It may be proposed as a diagnostic test for facet-mediated axial mid-back pain, as a therapeutic injection in a narrowly selected patient, or as part of management for a thoracic facet synovial cyst or effusion. Coverage is highly dependent on the member product, the clinical purpose, the exact thoracic level, and whether the payer recognizes thoracic facet intervention at all.

The most important operational fact is that thoracic coverage varies more sharply than the shared cervical/thoracic CPT family suggests. Medicare LCDs include thoracic facet intervention within their covered architecture but limit diagnostic intra-articular blocks to documented anatomic restrictions preventing a medial branch block or to a supported therapeutic intra-articular pathway. UnitedHealthcare permits a diagnostic facet injection pathway but states that medial branch block is generally more appropriate and considers therapeutic facet injections unproven and not medically necessary. Aetna includes levels from C2-3 through L5-S1 in its diagnostic pathway but treats corticosteroid-containing facet injections as therapeutic and generally unproven. The Carelon June 2026 guideline expressly lists diagnostic or therapeutic thoracic facet intervention as not medically necessary except at the C7-T1 and T12-L1 junctions. Capital Blue Cross lists lumbar or cervical pain, not thoracic pain, in its covered indications. The Evolent 2026 guideline explicitly includes thoracic facet intervention, subject to client and product implementation.

Therefore, a successful authorization starts by determining whether the member-specific controlling policy recognizes thoracic facet intervention. If it does, the request must state diagnostic intra-articular injection, therapeutic intra-articular injection, or treatment of a facet synovial cyst or effusion; identify the exact level and side; and explain why the intra-articular route, rather than a thoracic medial branch block or another thoracic pain procedure, is clinically and operationally appropriate.

Back to procedure navigation

2

Procedure Library

Evidence at a Glance

Domain	Operational conclusion
Clinical presentation	Predominantly axial thoracic pain with functional impairment and findings compatible with facetogenic pain. Untreated radiculopathy generally argues against a routine facet pathway except when caused by a facet synovial cyst.
Diagnostic route	Medial branch block is commonly preferred before radiofrequency ablation. Medicare limits diagnostic intra-articular use to documented anatomic restrictions or a supported therapeutic intra-articular pathway.
Therapeutic use	Coverage is narrower. Medicare requires two successful diagnostic procedures, documented durable response, and a reason RFA cannot be performed. Some commercial policies consider therapeutic facet injections unproven.
Image guidance	Fluoroscopy or CT is expected. Image guidance is included in CPT 64490-64492 and is not separately reported. Ultrasound is noncovered or investigational under multiple policies.
Levels	CPT defines a cervical/thoracic region. Medicare generally allows one or two levels, unilateral or bilateral, per session per region.
Diagnostic response	Medicare uses at least 80% index pain relief consistent with the anesthetic for confirmatory testing. Commercial thresholds vary, including 50% or 80%.
Sedation	Moderate or deep sedation, general anesthesia, and MAC are generally not reasonable and necessary for routine facet injections under Medicare.
Coding	CPT 64490 reports the first cervical/thoracic level; 64491 reports a second level. CPT 64492 is a third/additional-level code, but Medicare LCDs generally consider three- or four-level procedures noncovered.
Primary denial risk	The record fails to explain why an intra-articular injection is requested instead of a medial branch block or fails to establish a covered therapeutic exception.

Back to procedure navigation

3

Procedure Library

Procedure Definition and Relevant Thoracic Anatomy

The thoracic facet joints are paired synovial joints formed by the inferior articular process of the vertebra above and the superior articular process of the vertebra below. They contribute to motion control and posterior column stability. Degeneration, capsular injury, inflammatory arthropathy, trauma, and joint effusion may be associated with axial thoracic pain. Imaging findings alone do not prove that a facet joint is the pain generator, because degenerative changes are common and clinical correlation is imperfect.

For an intra-articular injection, the needle tip is positioned within the joint capsule under fluoroscopic or CT guidance. Contrast may be used to confirm intra-articular spread and identify unintended vascular or extra-articular distribution. The clinician determines the level, side, injectate, and procedural technique. This operational resource does not instruct procedural technique; it focuses on the documentation and coverage consequences of the selected route.

Thoracic level terminology

• A facet level refers to the thoracic zygapophyseal joint treated, not the number of nerves, needle placements, or adjacent vertebral bodies.
• A bilateral injection at the same vertebral level remains one level for coding and utilization purposes, although laterality reporting rules apply.
• Cervical and thoracic facet injections share one CPT code family and one Medicare spinal region for many utilization limits. Cervical and thoracic sessions may therefore accumulate together under the controlling policy.
• The thoracic region must be distinguished from costovertebral and costotransverse joints, ribs, intercostal nerves, thoracic discs, compression fractures, and myofascial structures because each represents a different diagnostic and coding pathway.
• The cervicothoracic junction at C7-T1 and the thoracolumbar junction at T12-L1 require exact level documentation. Some payer policies treat these junctional levels differently from the remainder of the thoracic spine.
• CMS coding guidance may treat contiguous T12-L1 and L1-L2 interventions as one lumbar region for certain claims. The practice must verify the governing MAC article and report the actual joints treated.

Back to procedure navigation

4

Procedure Library

Distinguishing Intra-Articular Injection from Other Facet Procedures

Procedure	Target	Typical operational purpose	Key coverage issue
Thoracic intra-articular facet joint injection	Thoracic zygapophyseal joint capsule and intra-articular space	Diagnostic injection in a limited pathway or therapeutic injection for a narrowly covered indication	The payer must recognize thoracic IA intervention; explain why IA is appropriate and whether RFA is contemplated.
Thoracic medial branch block	Thoracic medial branch nerves innervating the suspected facet joint	Diagnostic or prognostic test before thoracic medial branch RFA	Threshold, number of blocks, level, laterality, and regional frequency must match the payer pathway.
Thoracic medial branch radiofrequency ablation	Thoracic medial branch nerves	Longer-duration treatment after qualifying diagnostic blocks	Many payers require successful MBBs and may not accept IA injection as the prognostic test.
Thoracic interlaminar or transforaminal epidural steroid injection	Thoracic epidural space or exiting nerve root	Thoracic radicular pain or radiculopathy	Different indication, anatomy, CPT family, safety profile, and documentation requirements.
Costotransverse or costovertebral joint injection	Rib-vertebral articulation	Suspected rib-joint pain	Not a thoracic facet joint injection; document the actual joint and use the applicable coding pathway.
Intercostal nerve block	Intercostal nerve	Chest-wall or intercostal neuralgia pathway	Different target, indication, and CPT family.
Trigger point injection	Muscle trigger point	Myofascial thoracic pain	Does not establish facet-mediated pain and should not be substituted for a facet intervention.

Authorization integrity rule

Do not submit a generic request for a thoracic facet injection. Specify intra-articular versus medial branch, diagnostic versus therapeutic intent, exact joint level, side, planned image guidance, and the downstream treatment plan. Ambiguous terminology is a frequent source of mismatched authorizations and claim denials.

Back to procedure navigation

5

Procedure Library

Clinical Indications and Patient Selection

A payer-compliant thoracic facet record typically describes chronic, predominantly axial thoracic pain that produces functional limitation and is not better explained by nerve-root compression, myelopathy, fracture, tumor, infection, significant deformity, or another non-facet pain generator. The history and examination may support facet loading pain, paraspinal tenderness, reduced painful range of motion, or a referral pattern compatible with thoracic facet pain, but no single examination maneuver confirms the diagnosis.

Potentially supportable diagnostic scenario

• Moderate to severe axial thoracic pain lasting at least the policy-required duration, commonly three months.
• Documented functional deficit using a consistent pain or disability instrument.
• Failure of tolerated noninvasive conservative management.
• No untreated radiculopathy, neurogenic claudication, myelopathy, or competing pathology that better explains the symptoms.
• A clear plan to use the diagnostic result in treatment decision-making.
• For Medicare, a documented anatomic reason a medial branch block cannot be performed or a supported indication to proceed with therapeutic intra-articular injections.

Potentially supportable therapeutic scenario

• The patient meets all general facet intervention requirements and the member-specific policy recognizes therapeutic thoracic IA treatment.
• Required diagnostic procedures produced the policy-defined response.
• The record explains why RFA is not appropriate or cannot be performed when required.
• For a facet cyst or effusion pathway, current imaging demonstrates exact level and side concordance with the clinical syndrome.
• For repeat treatment, the prior injection produced the required magnitude and duration of pain or functional improvement.
• The authorization team has confirmed that a thoracic exclusion does not apply. Carelon, for example, lists thoracic facet interventions as not medically necessary except at C7-T1 and T12-L1 under its June 2026 guideline.

Back to procedure navigation

6

Procedure Library

Contraindications and Safety Considerations

Contraindications and precautions are clinician-determined and may include infection, uncontrolled coagulopathy, allergy to required medication or contrast, inability to safely position, unstable medical disease, pregnancy-related imaging considerations, and anatomy that prevents safe access. The authorization and scheduling workflow should verify that relevant risks were assessed without substituting administrative review for medical judgment.

• Active systemic infection or local infection at the access site.
• Uncorrected bleeding disorder or anticoagulant/antiplatelet management that is inconsistent with the clinician-approved plan.
• Uncontrolled medical instability or inability to cooperate with the procedure.
• Known allergy or prior severe reaction requiring an alternative medication or contrast strategy.
• Clinical evidence of myelopathy, progressive neurologic deficit, or another condition requiring a different pathway.
• Prior fusion at the proposed level when the controlling policy excludes or restricts facet intervention at a fused segment.
• Generalized pain syndromes or central sensitization when the record does not establish a localized facet pain generator.
• Routine moderate or deep sedation that could interfere with diagnostic validity or lacks separate medical necessity.

Back to procedure navigation

7

Procedure Library

Medical Necessity Requirements

Medical necessity is not established by a diagnosis code, degenerative imaging, or a procedure order alone. The record must link the patient presentation to the selected joint, explain the intended role of the injection, and satisfy the governing policy. The minimum operational dataset should be captured before submission.

Required element	What the record should show	Denial risk when missing
Pain pattern	Predominantly axial thoracic pain; location, side, duration, severity, aggravating activities, and referral pattern	Payer interprets the case as nonspecific thoracic spine pain or radiculopathy
Functional deficit	Specific limited ADLs, work, sleep, driving, self-care, or activity with baseline scale	No objective basis for intervention or repeat treatment
Examination	Facet loading or other concordant findings, neurologic assessment, and absence of a better pain generator	No clinical evidence of facetogenic pain
Imaging	Relevant thoracic imaging and exclusion of fracture, tumor, infection, or other dominant pathology	Imaging does not support the request or shows another cause
Conservative care	Dates, modalities, adherence, response, intolerance, or contraindication	Insufficient treatment duration or vague failure statement
Procedure intent	Diagnostic or therapeutic, exact levels and laterality, and how the result changes management	Generic request or no pathway
IA route rationale	Why injection into the joint is appropriate instead of MBB	Route-specific denial
RFA relationship	Whether RFA is being considered and, if not, the documented reason	Diagnostic request denied because RFA is not planned or therapeutic request denied because RFA is feasible
Prior response	Percent pain relief, duration, functional improvement, medication change, and same scale	Repeat criteria not met

Back to procedure navigation

8

Procedure Library

Conservative Treatment and Care-Pathway Sequencing

Most policies that recognize thoracic facet intervention require a documented trial of noninvasive care before an initial procedure. Medicare LCDs use a minimum three-month pain duration with failure of noninvasive conservative management as tolerated. UnitedHealthcare requires at least four weeks of conservative care for an initial diagnostic facet injection. Aetna requires six or more weeks. Evolent requires a documented multimodal conservative program under its client guideline. Capital Blue Cross should not be used as a thoracic coverage model because its listed covered indications are lumbar or cervical pain. The operational rule is first to confirm thoracic eligibility, then meet the most restrictive controlling requirement.

• Medication management when appropriate, including non-opioid analgesics or anti-inflammatory treatment.
• Physical therapy or a physician-directed home exercise program with dates and adherence.
• Activity modification, ergonomic intervention, posture or movement training, heat, cold, or other tolerated modalities.
• Documentation of contraindications, intolerance, lack of access, or clinical reasons a modality could not be completed.
• Reassessment showing persistent pain and functional impairment despite the completed plan.
• Continuation of a comprehensive pain-management plan rather than an injection-only strategy.

Sequencing principle

When RFA is the anticipated endpoint, the clinician and authorization team should verify whether the payer requires medial branch blocks rather than intra-articular injections. When therapeutic intra-articular injection is requested, the record should establish the specific exception pathway before authorization is submitted. Do not assume a successful intra-articular diagnostic injection will qualify the patient for RFA under every payer.

Back to procedure navigation

9

Procedure Library

CMS National Guidance and NCD Review

Medicare does not have a procedure-specific National Coverage Determination that independently establishes national coverage criteria for routine thoracic intra-articular facet joint injection. Coverage is primarily governed by the beneficiary benefit, Social Security Act reasonable-and-necessary standards, Medicare manuals, the applicable MAC LCD, and the companion billing and coding article. The absence of an NCD is not a coverage guarantee.

National authority	Operational relevance
Social Security Act Section 1862(a)(1)(A)	Services must be reasonable and necessary for diagnosis or treatment.
Social Security Act Section 1833(e)	Payment requires sufficient information to determine the amount due.
Medicare Claims Processing Manual	Controls claim reporting, bilateral services, radiology rules, and other payment mechanics.
National Correct Coding Initiative	Controls code-pair edits and correct coding. Verify the current quarterly files.
Medicare Benefit Policy Manual	Provides general benefit and exclusion principles, including restrictions on noncovered substances or services.

Back to procedure navigation

10

Procedure Library

Medicare LCD Requirements

Active multi-MAC LCDs for facet joint interventions use substantially similar coverage architecture, but the practice must identify the exact LCD governing the beneficiary and place of service. Examples include L33930, L34892, L38841, L39240, and related contractor policies. Effective dates, article pairings, diagnosis lists, and jurisdictional details can change.

Core Medicare criteria

• Moderate to severe chronic thoracic spine pain that is predominantly axial and causes a functional deficit measured on a pain or disability scale.
• Pain present for at least three months with documented failure of noninvasive conservative care as tolerated.
• Absence of untreated radiculopathy or neurogenic claudication, except radiculopathy caused by a facet synovial cyst.
• No non-facet pathology that better explains the pain, including fracture, tumor, infection, or significant deformity.
• Baseline pain assessment and disability scale, with the same pain scale used after diagnostic procedures.
• Fluoroscopy or CT guidance. Ultrasound-guided facet procedures are not covered under the cited LCD/article family.
• Only one spinal region per session and generally one or two levels, unilateral or bilateral, per session per region.
• No routine predetermined series.
• Routine moderate or deep sedation, general anesthesia, and MAC are not considered reasonable and necessary for facet injections.

Medicare diagnostic intra-articular rule

The cited LCD states that diagnostic intra-articular facet blocks are reasonable and necessary only when medial branch blocks cannot be performed because of specific documented anatomic restrictions or when there is an indication to proceed with therapeutic intra-articular injections. The restriction must be documented and available on request. Diagnostic procedures should be performed with the intent that RFA would be considered the primary treatment goal if the diagnostic pathway is successful.

A second diagnostic procedure may be covered at the same level, generally at least two weeks after the first, when the first produced at least 80% relief of the index pain for a duration consistent with the agent used. No more than four diagnostic sessions per covered spinal region are generally reimbursed in a rolling 12-month period.

Medicare therapeutic intra-articular rule

Therapeutic facet injections require two medically reasonable and necessary diagnostic facet procedures, each producing at least 80% relief of the index pain. Repeat therapeutic treatment at the same site must produce at least 50% pain relief for at least three months or at least 50% improvement in previously painful movements and ADLs using the same baseline scale. The record must explain why the patient is not an RFA candidate, such as established pseudarthrosis or an implanted electrical device. No more than four therapeutic sessions per covered spinal region are generally reimbursed in a rolling 12-month period.

Source: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33930&ver=49

Back to procedure navigation

11

Procedure Library

Medicare Billing and Coding Articles and MAC Variation

The companion billing article is as important as the LCD. It controls diagnosis lists, laterality, KX use, utilization parameters, documentation, and coding details. A56670 is one example; other MACs may use A57787, A58350, A58403, or another related article. Do not copy one MAC article across all states.

Article control	Example requirement from A56670	Operational action
Level counting	Count the facet joints treated, not the number of nerves or needles.	Reconcile order, authorization, operative report, and claim by joint level.
Laterality	Use RT or LT for unilateral treatment and modifier 50 for bilateral treatment; missing laterality can cause rejection.	Build laterality into authorization and charge reconciliation.
Regions	Cervical and thoracic are one CPT region.	Count all cervical/thoracic facet sessions together when applying regional rules.
Levels	One or two levels, unilateral or bilateral, are allowed per session per region under the cited article/LCD.	Do not schedule a third covered Medicare level without confirming noncoverage and beneficiary notice requirements.
KX	KX is required on diagnostic injections under the cited article.	Apply only when the applicable MAC article requires it and the record meets the policy.
ASC bilateral reporting	Physician uses modifier 50; ASC facility reports two lines with RT and LT.	Separate professional and facility claim logic.
Sedation	Anesthesia reported with routine facet injection is denied absent a separately supported exception.	Do not assume sedation is bundled or covered.
NCCI/OPPS	Codes remain subject to NCCI and OPPS packaging edits.	Verify current edits and setting-specific payment rules before claim release.

Source: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56670

Back to procedure navigation

12

Procedure Library

Medicare Hospital Outpatient Prior Authorization

Facet joint interventions are included in the Medicare prior authorization program for certain hospital outpatient department services. This is distinct from ordinary MAC medical-necessity review and distinct from commercial prior authorization. The hospital outpatient department must determine whether the requested CPT code is on the current CMS list, obtain provisional affirmation when required, and place the required unique tracking number on the claim. Office and ASC workflows may be different.

• Confirm that the service will be performed in a hospital outpatient department and that the code is currently subject to the program.
• Verify the current CMS submission channel, documentation checklist, review timeframe, and resubmission process.
• A provisional affirmation is not a guarantee of payment; eligibility, coding, medical necessity, and claim requirements still apply.
• CMS removed third/additional-level facet injection codes from the prior authorization list after Medicare policy established that three- and four-level procedures are noncovered. Verify the current code list rather than relying on an old authorization template.
• Keep the provisional affirmation decision and tracking number in the authorization and billing record.

Source: https://www.cms.gov/data-research/monitoring-programs/medicare-fee-service-compliance-programs/prior-authorization-pre-claim-review-initiatives/prior-authorization-certain-hospital-outpatient-department-opd-services

Back to procedure navigation

13

Procedure Library

Commercial Payer Policies

Commercial policies vary materially in how they treat intra-articular injection. Some group intra-articular injections and medial branch blocks under a single diagnostic policy, while others explicitly prefer medial branch blocks or exclude diagnostic intra-articular treatment. Benefit exclusions and delegated UM arrangements can be more restrictive than a national medical policy.

Payer / policy	Relevant 2026 position	Operational consequence
UnitedHealthcare Commercial and Individual Exchange	An initial diagnostic facet injection or MBB may be covered after at least four weeks of conservative care when facet loading is present, no better cause exists, the segment is not fused, and RFA is considered. A positive response is at least 50% for the expected anesthetic duration plus functional improvement. Therapeutic facet injections are unproven and not medically necessary.	A therapeutic thoracic IA request is high-risk. For diagnostic requests, document RFA intent, absence of untreated radiculopathy, exact level and side, and the response-measurement plan.
Aetna CPB 0016	An initial IA injection or MBB from C2-3 through L5-S1 may be diagnostic when chronic pain, facet findings, no better cause, functional limitation, more than three months of pain, at least six weeks of conservative care, and RFA consideration are documented. A second block requires 80% relief. Corticosteroid-containing facet injections are therapeutic and generally unproven for neck or back pain.	Thoracic levels fall within the stated anatomic range, but therapeutic steroid use remains noncovered under the policy. Separate diagnostic local-anesthetic intent from therapeutic intent.
Capital Blue Cross MP 4.050	The May 2026 policy lists lumbar or cervical pain in its covered diagnostic indications. Thoracic pain is not listed, and services for indications outside the listed criteria are investigational.	Do not infer thoracic coverage from the code list or the presence of thoracic diagnosis codes. Verify product applicability and consider the thoracic request outside the standard covered pathway unless the plan confirms otherwise.
Cigna / Evernorth	Selected plans use eviCore criteria; effective versions and client addenda vary.	Retrieve the client-specific guideline and code list. Do not apply a generic Cigna or eviCore rule without confirming delegation and effective date.
Humana	Coverage and prior authorization are product-, state-, and line-of-business-specific; Medicare Advantage, commercial, and Medicaid policies may differ.	Use the member-specific code search, authorization list, and coverage policy. Do not generalize one state or product policy nationally.

Source: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/facet-joint-injections-spinal-pain.pdf

Source: https://www.aetna.com/cpb/medical/data/1_99/0016.html

Source: https://www.capbluecross.com/wps/portal/cap/home/find/medical-policy/active-policies/facet-joint-injections-medial-branch-blocks

Back to procedure navigation

14

Procedure Library

BCBS Policy Variation

Blue Cross Blue Shield plans are independent organizations. There is no single national BCBS medical-necessity rule for thoracic intra-articular facet injection. A plan may use its own policy, the FEP policy, Carelon, eviCore, Evolent, or another UM arrangement. The authorization team must identify the home plan, product, network, utilization manager, code list, and site-of-service requirement.

• Capital Blue Cross MP 4.050 is a plan-authored example, but its covered diagnostic indications specify lumbar or cervical pain rather than thoracic pain. Thoracic requests therefore fall outside the listed covered indication under that policy.
• Some Blue plans delegate interventional pain review to Carelon. Carelon expressly lists thoracic facet intervention as not medically necessary except at C7-T1 and T12-L1 under its June 2026 guideline.
• Other Blue plans may delegate to eviCore or Evolent. Evolent explicitly includes thoracic facet intervention in its 2026 guideline, while client implementation and benefits still control.
• FEP members may be governed by a separate FEP policy manual.
• Host-plan and home-plan rules can affect where authorization is obtained for out-of-area members.
• A thoracic diagnosis code appearing in a policy coding table does not override an indication section that limits coverage to cervical or lumbar pain.

Back to procedure navigation

15

Procedure Library

Carelon, eviCore, Cohere, and Evolent

Carelon Medical Benefits Management

Carelon Interventional Pain Management criteria effective June 14, 2026 define the covered facet regions as cervical or lumbar and list diagnostic or therapeutic intra-articular injection, medial branch block, or RFA in the thoracic region as not medically necessary, except at C7-T1 and T12-L1. This is a direct thoracic exclusion, not merely an absence of criteria. A request for a mid-thoracic IA injection under a Carelon-governed product should therefore not be submitted as though the cervical criteria apply. Verify the plan addendum, benefit, and appeal rights before scheduling.

Source: https://guidelines.carelonmedicalbenefitsmanagement.com/interventional-pain-management-2026-06-14/

eviCore by Evernorth

eviCore manages selected payer and employer products, but public resources do not establish one universal thoracic IA standard. Versions, client addenda, code lists, and portal logic vary. Retrieve the exact client guideline effective for the member and date of service, determine whether thoracic facet intervention is covered or excluded, and preserve the guideline and portal response in the authorization record. Do not apply an upcoming version before its effective date.

Source: https://www.evicore.com/cigna

Cohere Health

Cohere manages musculoskeletal prior authorization for selected plans, but its public provider resources do not establish a single universal thoracic IA policy. Verify the payer-product delegation, CPT scope, portal questions, required documentation, effective date, and whether the review uses payer-authored criteria or Cohere logic. Save the submitted clinical packet and portal decision in the permanent authorization record.

Source: https://www.coherehealth.com/provider/resources

Evolent / RadMD

Evolent Clinical Guideline 1753 for 2026 explicitly includes intra-articular injections and medial branch blocks in the lumbar, cervical, and thoracic spine. The guideline requires a documented clinical and functional assessment, nonresponsiveness to conservative treatment, image guidance, and client-specific authorization. It allows up to two diagnostic injections in the initial phase, generally at least two weeks apart, with at least 50% pain relief or significant functional improvement for a same-level second injection. Therapeutic repeats require at least 50% pain relief or significant functional improvement for a minimum of two months. Client implementation, line of business, and benefit exclusions remain controlling.

Source: https://www1.radmd.com/sites/default/files/2026-05/2026%20Evolent%20Interventional%20Pain%20Management%20Guidelines.pdf

Back to procedure navigation

16

Procedure Library

Clinical Evidence and Specialty-Society Guidance

Clinical evidence and payer policy answer different questions. Thoracic evidence is substantially smaller than the cervical and lumbar evidence base. A study or specialty-society recommendation may support clinical plausibility or selected benefit, while a payer may still exclude thoracic intervention or require a different diagnostic pathway. Evidence should not be extrapolated across spinal regions without qualification.

ASIPP 2020 facet guidelines

ASIPP reported Level II evidence with moderate strength of recommendation for diagnostic thoracic facet nerve blocks using controlled comparative local-anesthetic blocks and a criterion standard of at least 80% relief. For therapeutic thoracic interventions, ASIPP reported Level II evidence with moderate recommendation for thoracic facet nerve blocks, Level III emerging evidence for thoracic radiofrequency ablation, and Level III evidence with weak-to-moderate recommendation for thoracic intra-articular facet injections based on one randomized trial with six-month follow-up. These categories are not interchangeable: support for thoracic nerve blocks does not establish equivalent evidence for thoracic IA steroid injection.

Source: https://asipp.org/wp-content/uploads/2020/11/REF1MA1.pdf

Thoracic intra-articular comparative study

A randomized comparative study evaluated thoracic intra-articular steroid injection and thoracic medial branch block in selected patients with thoracic facet joint pain. The study contributes directly relevant thoracic evidence, but its size, selection method, follow-up, and single-study status limit broad conclusions. It should be presented as supportive but not definitive evidence and does not override a payer exclusion.

Source: https://pubmed.ncbi.nlm.nih.gov/28591071/

Payer evidence reviews

UnitedHealthcare states that evidence is insufficient to assess the efficacy and safety of facet joint injections for chronic thoracic or cervical spinal pain and classifies therapeutic facet injections as unproven and not medically necessary. Carelon cites the thoracic comparative study but still expressly excludes thoracic facet interventions other than the C7-T1 and T12-L1 junctions. This illustrates why evidence review and coverage policy must be presented separately.

Source: https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/facet-joint-injections-spinal-pain.pdf

Source: https://guidelines.carelonmedicalbenefitsmanagement.com/interventional-pain-management-2026-06-14/

Evidence limitations

• Thoracic facet pain is less studied than cervical and lumbar facet pain.
• Facet degeneration on imaging does not reliably identify the symptomatic joint.
• Diagnostic blocks can produce false-positive results because of placebo response, spread outside the joint, sedation, activity restriction, or nonstandard outcome measurement.
• Therapeutic steroid evidence is limited by small samples, variable injectates, inconsistent selection criteria, and few thoracic-specific trials.
• Evidence from cervical or lumbar IA injections should not be applied to the thoracic spine without qualification.
• A payer threshold for a positive block is a coverage rule, not a universally accepted clinical truth.

Back to procedure navigation

17

Procedure Library

Policy and Guideline Comparison Matrix

Source	Thoracic diagnostic IA position	Thoracic therapeutic IA position	Operational controls
Medicare LCD family	Potentially covered only if MBB cannot be performed because of documented anatomy or there is a supported therapeutic IA pathway.	Potentially covered after two qualifying diagnostic procedures and documentation of why RFA cannot be performed.	At least 80% relief for diagnostic confirmation; up to 4 diagnostic and 4 therapeutic sessions per covered region in a rolling 12 months; generally 1-2 levels per session.
UnitedHealthcare 2026	Facet injection or MBB may be diagnostic; MBB is generally more appropriate and RFA must be considered.	Therapeutic facet injections are unproven and not medically necessary.	At least 50% relief for expected anesthetic duration plus functional improvement for a positive diagnostic response.
Aetna CPB 0016	IA or MBB from C2-3 through L5-S1 may be diagnostic after chronic pain, exam, imaging exclusion, 6 weeks conservative care, and RFA consideration.	Corticosteroid-containing facet injections are therapeutic and generally unproven for neck or back pain.	Second diagnostic requires 80% relief; no additional same-level diagnostic sets.
Capital Blue Cross MP 4.050	Thoracic pain is not listed in the covered diagnostic indications, which specify lumbar or cervical pain.	Thoracic treatment is outside the listed covered pathway.	Treat as investigational under the plan-authored policy unless the member product or plan confirms an exception.
Carelon 2026	Thoracic IA, MBB, and RFA are listed as not medically necessary except at C7-T1 and T12-L1.	Same thoracic exclusion applies.	Do not apply cervical or lumbar criteria to mid-thoracic levels. Verify the plan addendum and appeal pathway.
Evolent 2026	Explicitly includes thoracic facet intervention; up to two diagnostic injections in the initial phase under stated criteria.	Therapeutic repeats may be considered after qualifying response.	At least 50% relief or significant functional improvement; repeat timing and client rules apply.
eviCore / Cohere	Client-specific.	Client-specific.	Verify live guideline, plan addendum, effective date, CPT scope, and portal logic.

Back to procedure navigation

18

Procedure Library

Prior Authorization Workflow

1. Identify the payer, member product, benefit status, network, delegated UM entity, authorization channel, and intended place of service.

2. Confirm whether CPT 64490 and 64491 require prior authorization and whether hospital outpatient Medicare prior authorization applies.

3. Retrieve the live policy, LCD, billing article, vendor guideline, code list, and effective date. Save them to the case record.

4. Clarify the requested procedure as thoracic intra-articular facet joint injection, not generic facet injection or MBB.

5. Confirm diagnostic versus therapeutic intent, exact joint level, side, and injectate category.

6. Determine whether RFA is being considered. If not, identify the payer-recognized reason.

7. For Medicare diagnostic IA, obtain the documented anatomic restriction preventing MBB or the supported therapeutic IA pathway.

8. Validate chronicity, axial pain pattern, functional deficit, examination, neurologic status, and imaging exclusion of other pathology.

9. Validate conservative-care dates, modalities, adherence, response, and contraindications.

10. Count all cervical/thoracic facet sessions in the payer look-back period, including MBB, IA, cyst procedures, and RFA when the policy defines a session broadly.

11. For repeat or confirmatory requests, capture percent relief, duration, functional improvement, same scale, and exact prior level and side.

12. Reconcile rendering provider, facility, requested dates, units, laterality, and authorization validity.

13. Submit an indexed clinical packet or concise policy-mapped summary.

14. Track requests for information, peer-to-peer deadlines, appeal rights, and expiration.

15. Before the procedure, reconcile the authorization with the schedule and physician order.

16. After the procedure, reconcile the operative report and claim and capture outcomes for the next decision.

Back to procedure navigation

19

Procedure Library

Clinical Documentation Requirements

Initial diagnostic request

• Chief complaint, onset, duration, location, laterality, severity, and predominantly axial pattern.
• Specific functional limitations and baseline pain/disability instrument.
• Physical examination with facet loading or other concordant findings and neurologic assessment.
• Thoracic imaging date and findings, including exclusion of fracture, tumor, infection, significant deformity, or dominant nerve-root pathology.
• Conservative treatment dates, components, adherence, response, and exceptions.
• Exact requested facet joint level and side.
• Diagnostic intent and how the result will change management.
• Whether RFA is being considered.
• For Medicare IA, the specific anatomic restriction preventing MBB or the supported indication for a therapeutic IA pathway.
• Planned fluoroscopic or CT guidance.
• Medication and contrast considerations and relevant anticoagulation or infection assessment.

Confirmatory diagnostic request

• Date, level, side, CPT, and type of the first diagnostic procedure.
• Baseline and post-procedure pain scores using the same scale.
• Percent relief and duration compared with expected local anesthetic action.
• Specific functional change during the diagnostic window.
• Confirmation that the same level and side are being requested.
• Required interval since the initial procedure or documented exception.
• Continued intent to use the result in an RFA or covered therapeutic pathway.

Therapeutic request

• Payer-recognized therapeutic indication and why IA treatment is appropriate.
• Results of required diagnostic procedures.
• Why RFA cannot be performed or is contraindicated when required.
• For inflammatory arthropathy, a clear diagnosis and assessment linking inflammation to the treated joint.
• For facet cyst or effusion, recent MRI or CT, level/side concordance, nerve-root compression, radicular symptoms, and functional limitation.
• For repeat treatment, prior pain relief, duration, functional improvement, and same scale.
• Frequency and level compliance.

Procedure report

• Pre- and post-procedure diagnosis and indication.
• Diagnostic or therapeutic intent.
• Exact thoracic joint level and laterality.
• Image-guidance method and contrast findings.
• Confirmation of intra-articular placement or documentation of technical limitation.
• Medication name, concentration, and volume.
• Sedation, if any, and separate medical necessity.
• Complications and disposition.
• Immediate pain and function response when diagnostic interpretation is intended.
• Follow-up plan and outcome-measure instructions.

Back to procedure navigation

20

Procedure Library

Documentation Pearls

• Use the phrase thoracic intra-articular facet joint injection consistently. Do not alternate between IA, MBB, facet block, and trigger point injection.
• State the joint level, not only the vertebral body or nerve name.
• Explain why the intra-articular route was selected. This is the highest-value sentence in many IA authorizations.
• Do not describe steroid-containing injection as purely diagnostic when the payer defines corticosteroid use as therapeutic.
• Document baseline function before the first procedure; it cannot be reconstructed credibly after a denial.
• For a positive block, record percentage, duration, activities performed, and the exact scale. The word helpful is insufficient.
• When the patient is not an RFA candidate, identify the actual contraindication rather than stating not a candidate without explanation.
• Do not rely on imaging degeneration alone. Connect findings to the history, examination, and excluded alternatives.
• Keep authorization, order, schedule, operative note, and claim aligned by route, level, side, and intent.
• Treat payer effective dates as clinical-operational data. Save the version used for each decision.

Back to procedure navigation

21

Procedure Library

CPT and HCPCS Coding

Code	General descriptor role	Thoracic IA application	Operational control
64490	Paravertebral facet joint injection or nerves innervating the joint, cervical/thoracic, first level, with fluoroscopy or CT	Report the first treated thoracic facet level, whether unilateral or bilateral, subject to modifier rules.	Image guidance is included. The code does not distinguish IA from MBB, so documentation must.
64491	Cervical/thoracic, second level, add-on code	Report a second distinct cervical/thoracic facet level in the same session when covered.	Use only with the required primary code and verify payer bilateral logic.
64492	Cervical/thoracic, third and any additional level, add-on code	CPT recognizes the code, but Medicare LCDs generally deem three- or four-level procedures noncovered.	Do not infer coverage from code existence. Verify payer policy and beneficiary notice requirements.
77003 / 77012	Fluoroscopy or CT guidance codes	Generally not separately reportable with 64490-64492 because guidance is included.	Avoid unbundling and verify NCCI.
Drug HCPCS J-codes	May describe separately payable drugs in some settings	Payment depends on payer, setting, packaging, and drug policy.	Do not promise separate payment; verify units, NDC requirements, and packaging.

Coding boundaries

• The cervical/thoracic facet code family covers injection into the joint or the nerves innervating it. The procedure note must identify IA versus MBB.
• Report by facet joint level, not by the number of needle placements or nerves.
• A bilateral injection at the same level is one level, with payer-specific bilateral reporting.
• The CPT cervical/thoracic region is distinct from the lumbar/sacral region.
• Do not separately bill image guidance included in the facet code.
• Verify the current CPT manual and payer edits for each date of service.

Back to procedure navigation

22

Procedure Library

ICD-10-CM Crosswalk

Diagnosis coding must reflect the documented condition and the payer/MAC list. The following is a focused operational crosswalk, not a complete code list or a coverage guarantee. A cited MAC article currently lists a limited set of spondylosis and ankylosing hyperostosis codes for facet injection and RFA. Other MACs and commercial payers may differ.

ICD-10-CM	Description	Operational use / caution
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Common thoracic facet diagnosis when the signed record establishes predominantly axial facet-mediated pain; verify the MAC or payer list.
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Use when the documented pathology and treated joint are at the cervicothoracic region and the payer accepts the code.
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Use only when the documented condition and exact treated level support thoracolumbar coding.
M47.894	Other spondylosis, thoracic region	Use only when the record supports other thoracic spondylosis and the controlling article accepts it.
M47.893	Other spondylosis, cervicothoracic region	Plan- and MAC-specific; confirm both clinical accuracy and policy compatibility.
M47.895	Other spondylosis, thoracolumbar region	Confirm the exact level and governing article before use.
M48.14	Ankylosing hyperostosis [Forestier], thoracic region	May support coverage under some MAC articles when clinically documented and accepted by the payer.
M48.13 / M48.15	Ankylosing hyperostosis, cervicothoracic / thoracolumbar region	Use only when the region and diagnosis are clinically accurate and accepted by the controlling policy.
M54.6	Pain in thoracic spine	A symptom code may be insufficient under a limited Medicare diagnosis list and does not by itself establish facet-mediated pain.
M54.14	Radiculopathy, thoracic region	Routine facet pathways generally exclude untreated radiculopathy. It may be relevant to a documented facet cyst exception, subject to payer-specific coding.
M71.30 / M71.38	Other bursal cyst codes	Some MAC articles limit these codes to facet cyst aspiration or rupture rather than routine IA injection. Verify the exact procedure and article.

ICD-10-CM integrity warning

Do not select a diagnosis solely because it appears on a payer list. The code must match the signed clinical record and the procedure indication. Conversely, a clinically accurate code may still be noncovered under a specific MAC article. Both clinical accuracy and policy compatibility are required.

Back to procedure navigation

23

Procedure Library

Modifiers, Units, NCCI, MUE, and Place of Service

Control	Operational guidance
RT / LT	Use for unilateral treatment when required by the payer or MAC. The level and side must match the authorization and operative report.
Modifier 50	Commonly used by the physician for bilateral treatment at the same level. Confirm payer-specific claim formatting.
KX	Required for diagnostic injections under certain MAC articles such as A56670. Do not use automatically across all payers or therapeutic injections.
25	Use only when a significant, separately identifiable E/M service is documented beyond the usual pre-procedure work and payer rules permit.
59 or X modifiers	Use only to identify a truly distinct service after checking NCCI and payer policy. Not a tool to bypass bundling.
Units	Primary and add-on codes are level-based. Bilateral reporting varies by professional versus facility claim and payer.
NCCI / MUE	Check current quarterly NCCI edits and payer-specific MUE logic. Do not hard-code an old edit into the workflow.
POS 11	Office. Confirm benefit, authorization, and office-based procedure policy.
POS 19 / 22	Hospital outpatient. Medicare OPD prior authorization may apply.
POS 24	ASC. Professional and facility bilateral reporting may differ.

Back to procedure navigation

24

Procedure Library

Reimbursement Considerations

Reimbursement depends on coverage, authorization, coding, setting, contract, bilateral methodology, drug packaging, and documentation. A technically correct CPT code does not create payment when the service is noncovered under the clinical policy. Intra-articular facet injection has a particularly high mismatch risk because the same CPT code family also describes medial branch blocks while payer coverage may differ by route and intent.

• Verify professional and facility authorization requirements separately.
• Confirm whether the payer authorizes by CPT only or also records level, side, diagnosis, and setting.
• Reconcile bilateral methodology for professional, ASC, and hospital claims.
• Do not separately report image guidance included in the CPT descriptor.
• Confirm whether drugs are packaged or separately payable in the setting and contract.
• Confirm the authorization date range and number of sessions, not only the number of units.
• Use advance beneficiary notice or noncovered-service processes when appropriate and compliant; do not miscode a noncovered therapeutic injection as diagnostic.
• Track underpayments separately from medical-necessity denials because the root-cause workflow is different.

Back to procedure navigation

25

Procedure Library

Denial Prevention

Failure mode	Prevention control
IA route not justified	Require a route-rationale field in the order and authorization checklist.
MBB preferred by payer	Verify payer pathway before scheduling and obtain physician clarification before submission.
Therapeutic injection excluded	Identify the covered exception or change the clinical plan; do not submit generic axial pain as a therapeutic indication.
RFA not being considered	Document RFA intent for diagnostic pathways or the policy-recognized reason RFA is not appropriate.
Untreated radiculopathy	Distinguish facetogenic axial pain from radiculopathy; document a facet cyst exception when applicable.
No functional baseline	Capture a validated baseline scale and specific ADL limitations before the first procedure.
Conservative care vague	Use dated modality, duration, adherence, response, and exception fields.
Prior response incomplete	Capture percent, duration, same scale, functional change, and exact prior level/side.
Wrong level or laterality	Reconcile order, imaging, authorization, schedule, operative report, and charge.
Wrong intent on claim	Keep diagnostic/therapeutic intent and KX use aligned with the record and MAC article.
Third level denied	Apply Medicare one-to-two-level rule and payer-specific limits before scheduling.
Ultrasound guidance	Verify coverage; multiple policies consider it noncovered or investigational.
Sedation denial	Avoid routine anesthesia and document separately supported necessity when applicable.

Back to procedure navigation

26

Procedure Library

Common Denial Reasons and Corrective Actions

Denial reason	What to investigate	Corrective action
Not medically necessary	Was the request diagnostic or therapeutic? Did the policy allow IA?	Map the appeal to the exact IA pathway or acknowledge the policy exclusion and revise the plan.
MBB required	Does the payer prefer MBB before RFA?	Provide documented anatomic restriction or supported IA indication; otherwise discuss MBB pathway with clinician.
No RFA intent	Was the diagnostic result intended to guide RFA?	Submit explicit treatment plan or policy-recognized reason RFA cannot be used.
Insufficient conservative care	Dates, weeks, modalities, adherence, contraindications	Supply contemporaneous records and timeline; do not rely on a retrospective attestation alone.
Radiculopathy present	Is the pain primarily radicular or due to a facet cyst?	Clarify diagnosis and imaging; use the appropriate epidural or cyst pathway when clinically indicated.
Positive block not established	Threshold, duration, scale, activity, level/side	Submit outcome record with policy-specific threshold and same scale.
Frequency exceeded	All facet sessions in region and rolling period	Correct count, distinguish different region only if policy allows, or appeal with documented exception.
Coding/laterality mismatch	Authorization, operative report, claim line	Correct claim or obtain authorization correction before filing.
No RFA contraindication for therapeutic IA	Actual clinical reason and payer recognition	Submit specific contraindication and supporting records; generic preference is insufficient.
Experimental / unproven	Policy language and benefit document	Clinical evidence alone may not overcome a contractual exclusion; evaluate appeal rights and alternative covered pathway.

Back to procedure navigation

27

Procedure Library

Appeals and Peer-to-Peer Preparation

An effective appeal is policy-specific and route-specific. It should not simply restate that the patient has thoracic spine pain or failed therapy. The appeal must identify the exact denial rationale, quote or accurately summarize the controlling criterion, and show where the record satisfies it or why an exception is warranted.

Appeal packet

• Denial notice, authorization request, and original submitted records.
• Controlling policy, version, effective date, member product, and relevant criterion.
• One-page clinical chronology with pain duration, function, treatment, imaging, and prior response.
• Explicit explanation of diagnostic versus therapeutic intent.
• Specific rationale for IA rather than MBB.
• RFA intent or documented contraindication/non-candidacy.
• Exact level, side, image guidance, and coding alignment.
• Relevant society guidance or evidence when the appeal permits medical literature review.
• Requested remedy: overturn, peer review, external review, or authorization correction.

Peer-to-peer questions

• Which exact policy criterion is not met?
• Is the denial based on benefit exclusion, lack of medical necessity, route preference, or missing documentation?
• Would a medial branch block be covered when IA is not?
• What documentation would establish anatomic inability to perform MBB?
• What conditions qualify as an RFA contraindication under this policy?
• Is a therapeutic IA exception recognized for inflammatory arthropathy or facet cyst?
• What response threshold and interval apply to a confirmatory procedure?
• Can the authorization be corrected for level, side, or place of service without a new review?

Back to procedure navigation

28

Procedure Library

Workflow Optimization and Quality Controls

Workflow stage	Control
Intake	Require route, intent, exact level, laterality, payer, product, and place of service.
Policy research	Save the live policy and vendor guideline with effective date and access date.
Clinical review	Use an IA-specific checklist, not a generic facet checklist.
Physician clarification	Escalate when MBB versus IA, diagnostic versus therapeutic, or RFA pathway is unclear.
Submission	Send a policy-mapped summary and indexed supporting documents.
Scheduling	Hard-stop for authorization validity, level, side, code, and site.
Procedure day	Confirm order, consent, authorization, anticoagulation plan, and intended joint.
Charge entry	Reconcile CPT, add-on code, bilateral modifier, KX if applicable, diagnosis, and place of service.
Outcome capture	Collect same-scale pain response, duration, function, and next-step plan.
Audit	Review denials, route mismatches, level errors, authorization expirations, and response-documentation failures.

Back to procedure navigation

29

Procedure Library

Operational KPIs

KPI	Definition	Why it matters
Clean submission rate	Percent of requests submitted without missing policy-required elements	Measures intake and documentation discipline.
First-pass approval rate	Percent approved without additional information, peer-to-peer, or appeal	Shows policy alignment.
IA-to-MBB clarification rate	Percent requiring physician clarification of route	Identifies ordering ambiguity and training need.
Turnaround time	Days from complete intake to authorization decision	Supports scheduling and patient access.
Authorization-to-procedure match rate	Percent matching code, route, level, side, provider, site, and date	Prevents downstream denials.
Outcome capture rate	Percent with complete pain and functional outcomes after diagnostic or therapeutic injection	Protects confirmatory, repeat, and RFA pathways.
Denial rate by root cause	Medical necessity, route, documentation, frequency, coding, eligibility, or authorization	Directs process improvement.
Appeal overturn rate	Percent of appealed denials overturned	Measures appeal quality and policy defensibility.
Avoidable write-off rate	Dollars written off for preventable authorization or coding failures	Connects operations to revenue integrity.

Back to procedure navigation

30

Procedure Library

Payer Perspective

Payers scrutinize thoracic intra-articular facet injections because the diagnosis of facet-mediated pain is imperfect, imaging is nonspecific, diagnostic blocks can be false-positive, and evidence for therapeutic steroid injection is limited. Many policies prefer medial branch blocks for RFA selection and restrict therapeutic IA to exceptions. A strong request does not argue that every patient with thoracic spondylosis needs a facet injection. It demonstrates a localized, function-limiting condition, a completed conservative pathway, exclusion of competing pathology, and a policy-supported reason for the intra-articular route.

Back to procedure navigation

31

Procedure Library

Clinical Pearls

• Facet degeneration on MRI is not synonymous with facet-mediated pain.
• An intra-articular injection and a medial branch block answer related but not identical clinical questions.
• When RFA is the endpoint, confirm that the payer accepts IA as a prognostic test; many prefer MBB.
• Use the lowest volume consistent with the clinical plan because extra-articular spread can reduce diagnostic specificity.
• Avoid routine sedation during a diagnostic procedure when it could alter pain reporting and activity testing.
• Interpret immediate relief in context of the anesthetic used and the patient activities that normally provoke pain.
• Do not repeat an ineffective diagnostic block at the same level unless the payer recognizes a documented reason.
• At the C7-T1 and T12-L1 junctions, confirm whether the payer treats the level as an exception, a cervical/thoracic facet level, or part of a contiguous regional claim.

Back to procedure navigation

32

Procedure Library

GoHealthcare Perspective

Thoracic intra-articular facet injection is a test of operational precision. The CPT code alone does not reveal whether the clinician injected the joint or the medial branch nerves, whether the service was diagnostic or therapeutic, or whether the payer accepts the chosen pathway. The practice must create that clarity before authorization, not after a denial.

The strongest model is a closed-loop pathway: precise order, current policy, route-specific documentation, complete authorization, pre-procedure reconciliation, accurate operative report, claim validation, and structured outcome capture. When any link is missing, the next procedure, appeal, or claim becomes vulnerable.

Back to procedure navigation

33

Procedure Library

GoHealthcare Insights

• Build separate authorization templates for IA, MBB, RFA, and facet cyst procedures even though codes and payer policies may overlap.
• Use a mandatory field for why IA is selected instead of MBB.
• Create payer rules that distinguish diagnostic local-anesthetic injection from steroid-containing therapeutic injection.
• Count sessions across the entire cervical/thoracic region and across all facet intervention types when the policy defines session broadly.
• Do not permit scheduling from an approval that says thoracic facet injection without confirming route, level, and side.
• Capture outcomes within the expected anesthetic window and again for therapeutic duration.
• Track which payers reject therapeutic IA categorically and which recognize exceptions.
• Link denial analytics to physician documentation education and scheduling hard-stops.

Back to procedure navigation

34

Procedure Library

Frequently Asked Questions

Is thoracic intra-articular facet joint injection the same as a thoracic medial branch block?

No. IA injection enters the joint. MBB targets the nerves that innervate the joint. The same CPT family may apply, but coverage and clinical purpose can differ.

Which CPT code is used for the first thoracic facet level?

CPT 64490 generally reports the first cervical or thoracic facet level with fluoroscopy or CT, whether the service is IA or MBB. The operative note must identify the actual technique.

What code reports a second thoracic level?

CPT 64491 is the add-on code for a second cervical/thoracic facet level, subject to payer coverage and reporting rules.

Can CPT 64492 be billed for a third thoracic level?

CPT recognizes the third/additional-level code, but current Medicare LCDs generally consider three- or four-level procedures noncovered. Commercial policies vary.

Does Medicare cover diagnostic IA facet injection?

Only in a limited pathway under cited LCDs: when MBB cannot be performed because of documented anatomic restrictions or when there is a supported indication to proceed with therapeutic IA injection.

Does Medicare require two diagnostic procedures?

For a confirmatory pathway and for therapeutic facet coverage, current LCDs generally require qualifying diagnostic procedures with at least 80% relief as specified.

Does Medicare cover therapeutic thoracic IA injections?

Potentially, but only when strict criteria are met, including successful diagnostic procedures and documentation of why RFA cannot be performed.

Do commercial payers cover therapeutic IA injections?

Some do only under narrow exceptions; others classify therapeutic facet injections as unproven or not medically necessary. Verify the member-specific policy.

Is RFA required after a diagnostic injection?

Not automatically, but many diagnostic policies require that RFA be under consideration. Medicare states diagnostic procedures should generally be performed with RFA as the primary treatment goal if successful.

What is a positive diagnostic response?

The threshold is payer-specific. Medicare commonly uses at least 80%; UnitedHealthcare defines at least 50% for the expected anesthetic duration plus functional improvement; other policies vary.

Can ultrasound be used?

Clinically available techniques and coverage are separate questions. Medicare and multiple commercial policies consider ultrasound-guided facet injection noncovered or investigational.

Is fluoroscopy separately billable?

No, image guidance is included in CPT 64490-64492 and generally should not be separately reported.

Can the procedure be performed bilaterally?

Yes when clinically indicated and covered. Bilateral treatment at one level is still one level, but modifier and claim-line rules vary by setting and payer.

Can a thoracic facet injection be performed at a fused level?

Some policies exclude or restrict facet intervention at a fused motion segment. Confirm the exact policy and document the anatomy and pain generator.

Can radiculopathy support a thoracic facet injection?

Routine facetogenic pain pathways generally require absence of untreated radiculopathy. A facet synovial cyst causing nerve-root compression may be a specific exception under some policies.

What documentation is most often missing?

The IA route rationale, RFA plan or contraindication, functional baseline, conservative-care dates, and prior response measured with the same scale.

Does prior authorization guarantee payment?

No. Eligibility, benefit, coding, medical necessity, authorization match, provider status, and claim rules remain applicable.

What should be captured after the procedure?

Immediate pain response, duration, function, activities tested, medication change, complications, and next treatment decision.

Can IA injection qualify a patient for thoracic RFA?

Only if the payer accepts IA as the diagnostic or prognostic test. Many policies prefer or require medial branch blocks.

How should a denial be appealed?

Use the exact policy version, denial rationale, route-specific clinical facts, and requested remedy. Generic medical-necessity letters are less effective.

Back to procedure navigation

35

Procedure Library

Related Procedures

• Thoracic Medial Branch Block
• Thoracic Medial Branch Radiofrequency Ablation
• Cervical Intra-Articular Facet Joint Injection
• Lumbar Intra-Articular Facet Joint Injection
• Thoracic Interlaminar Epidural Steroid Injection
• Thoracic Transforaminal Epidural Steroid Injection
• Costotransverse or Costovertebral Joint Injection
• Intercostal Nerve Block
• Facet Joint Cyst Aspiration or Rupture
• Trigger Point Injection

Back to procedure navigation

36

Procedure Library

References and Related Readings

1. Centers for Medicare & Medicaid Services. LCD L33930, Facet Joint Interventions for Pain Management. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33930&ver=49

2. Centers for Medicare & Medicaid Services. LCD L38841, Facet Joint Interventions for Pain Management. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38841&ver=18

3. Centers for Medicare & Medicaid Services. Billing and Coding Article A56670. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56670

4. Centers for Medicare & Medicaid Services. Billing and Coding Article A57787. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57787

5. Centers for Medicare & Medicaid Services. Prior Authorization for Certain Hospital Outpatient Department Services. https://www.cms.gov/data-research/monitoring-programs/medicare-fee-service-compliance-programs/prior-authorization-pre-claim-review-initiatives/prior-authorization-certain-hospital-outpatient-department-opd-services

6. UnitedHealthcare. Facet Joint and Medial Branch Block Injections for Spinal Pain, effective May 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/facet-joint-injections-spinal-pain.pdf

7. Aetna. Clinical Policy Bulletin 0016, Back Pain - Invasive Procedures. https://www.aetna.com/cpb/medical/data/1_99/0016.html

8. Capital Blue Cross. MP 4.050, Facet Joint Injections and Medial Branch Blocks, effective May 1, 2026. https://www.capbluecross.com/wps/portal/cap/home/find/medical-policy/active-policies/facet-joint-injections-medial-branch-blocks

9. Carelon Medical Benefits Management. Interventional Pain Management, effective June 14, 2026. https://guidelines.carelonmedicalbenefitsmanagement.com/wp-content/uploads/2026/03/PDF-Interventional-Pain-Management-2026-06-14.pdf

10. eviCore by Evernorth. Cigna Musculoskeletal Guideline Resources. https://www.evicore.com/cigna

11. Cohere Health. Provider Resources. https://www.coherehealth.com/provider/resources

12. Evolent. 2026 Interventional Pain Management Guidelines. https://www1.radmd.com/sites/default/files/2026-05/2026%20Evolent%20Interventional%20Pain%20Management%20Guidelines.pdf

13. Lee DG, Ahn SH, Cho YW, et al. Comparison of Intra-articular Thoracic Facet Joint Steroid Injection and Thoracic Medial Branch Block for the Management of Thoracic Facet Joint Pain. Spine. 2018. https://pubmed.ncbi.nlm.nih.gov/28591071/

14. Manchikanti L, et al. ASIPP Comprehensive Evidence-Based Guidelines for Facet Joint Interventions. Pain Physician. 2020. https://asipp.org/wp-content/uploads/2020/11/REF1MA1.pdf

15. GoHealthcare Practice Solutions. Case Study Library. https://www.gohealthcarellc.com/case-studies.html

16. GoHealthcare Practice Solutions. Request Help. https://www.gohealthcarellc.com/contact-us.html

Back to procedure navigation

Strengthen Thoracic Facet Authorization and Revenue Integrity

GoHealthcare supports physician practices, ASCs, hospitals, and healthcare organizations with prior authorization, utilization management, clinical documentation review, denial prevention, appeals, coding alignment, and revenue-cycle operations for complex musculoskeletal procedures.

Request Help View Case Studies

Case Study Library: https://www.gohealthcarellc.com/case-studies.html

!

Disclaimer

This publication is provided for educational and operational purposes. It is not medical advice, legal advice, coding advice, a coverage guarantee, or a substitute for the member-specific benefit plan, current payer policy, Medicare NCD, LCD, billing article, utilization-management guideline, CPT instructions, ICD-10-CM Official Guidelines, NCCI edits, payer contract, or clinician judgment. Policies, code sets, prior authorization requirements, and payment rules change. Users must verify all requirements with the governing payer, MAC, utilization-management entity, and official coding sources for the member, date of service, provider, and place of service. GoHealthcare company-reported performance metrics are not a guarantee of results.